Drug resistance in the treatment of cancer

Drug resistance in the treatment of cancer

Enregistré dans:
Détails bibliographiques
Autres auteurs : Giaccone Giuseppe, Pinedo H. M.
Format : Livre
Langue : anglais
Titre complet : Drug resistance in the treatment of cancer / edited by Herbert M. Pinedo and Giuseppe Giaccone
Publié : Cambridge, U.K., New York : Cambridge University Press , c1998
Description matérielle : xvi, 323 p.
Collection : Cancer, clinical science in practice
Contenu : Resistance mechanisms to antimetabolites. Resistance to antitumor alkylating agents and cisplatin. The MDR genes. Topoisomerase genes and resistance to topoisomerase inhibitors. Genes that modulate apoptosis: major determinatns of drug resistance. Clinical implications of drug resistance. The reversal of multidrug resistance. Effect of dose and schedule on chemotherapeutic drug resistance. Circumvention of drug resistance by high-dose chemotherapy in solid tumors. Enhancing drug effectiveness by gene transfer
Sujets :
Cellules cancéreuses > Résistance aux médicaments
RESISTANCE MEDICAMENT ANTINEOPLASIQUE > PHYSIOLOGIE
ANTINEOPLASIQUES > USAGE THERAPEUTIQUE
Antineoplastic Agents > therapeutic use
Drug Resistance, Neoplasm > physiology
Drug resistance in cancer cells
LEADER 02225cam a2200445 4500
001 PPN02832076X
005 20031219080000.0
009 DYNIX_BUNAN_495233
010 |a 0-521-47321-7  |b hb 
020 |a US  |b 976482 
035 |a ocm36470679 
100 |a 19970224d1998 u u fre 0103 
101 0 |a eng 
102 |a GB  |b en 
105 |a a # 000|y 
200 0 |a Drug resistance in the treatment of cancer  |f edited by Herbert M. Pinedo and Giuseppe Giaccone 
210 |a Cambridge, U.K.  |a New York  |c Cambridge University Press  |d c1998 
215 |a xvi, 323 p.  |c ill.  |d 24 cm 
225 2 |a Cancer, clinical science in practice 
327 1 |a Resistance mechanisms to antimetabolites  |a Resistance to antitumor alkylating agents and cisplatin  |a The MDR genes  |a Topoisomerase genes and resistance to topoisomerase inhibitors  |a Genes that modulate apoptosis: major determinatns of drug resistance  |a Clinical implications of drug resistance  |a The reversal of multidrug resistance  |a Effect of dose and schedule on chemotherapeutic drug resistance  |a Circumvention of drug resistance by high-dose chemotherapy in solid tumors  |a Enhancing drug effectiveness by gene transfer 
410 |t Cancer, clinical science in practice 
606 1 |3 PPN027567931  |a Cellules cancéreuses  |3 031363695  |x Résistance aux médicaments  |2 rameau 
610 1 |3 PPN040835316  |a RESISTANCE MEDICAMENT ANTINEOPLASIQUE  |3 040760200  |x PHYSIOLOGIE  |2 fmesh 
610 1 |3 PPN040664007  |a ANTINEOPLASIQUES  |3 038961784  |x USAGE THERAPEUTIQUE  |2 fmesh 
610 2 |a Antineoplastic Agents  |x therapeutic use  |2 mesh 
610 1 |a Drug Resistance, Neoplasm  |x physiology  |2 mesh 
610 1 |a Drug resistance in cancer cells  |2 lc 
676 |a 616.99/4061  |v 21 
680 |a RC271.C5  |b D7778 1998 
686 |a QV 269  |b D7945 1998  |2 usnlm 
686 |a 1998 E-053  |2 usnlm 
702 1 |a Giaccone  |b Giuseppe 
702 1 |a Pinedo  |b H. M. 
801 2 |a FR  |b AUROC  |c 20001227  |g AFNOR 
801 1 |a US  |b OCLC  |c 20001227  |g AACR2 
801 3 |a FR  |b Abes  |c 20001227  |g AFNOR 
930 |5 441092101:166871214  |b 441092101  |l 495233  |a QZ 266 PIN  |j b 
979 |a SAN 
993 |a 0557639883  |b SAN  |c QZ 266 PIN  |d LETAG  |e SANT2  |f I  |g 28-06-2002  |h 24-10-2002  |k 130.00  |o 14-12-2002  |p 1  |s 63988  |t LETAG  |u SANT2  |v i 
998 |a 65054